Phibro Animal Health (PAHC) Cash from Financing Activities (2013 - 2026)
Phibro Animal Health (PAHC) posted quarterly Cash from Financing Activities of -$2.3 million for Q1 2026, up 92.86% year-over-year from -$1.2 million in Q1 2025, and up 87.88% quarter-over-quarter from -$19.0 million in Q4 2025.
Phibro Animal Health (PAHC) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Phibro Animal Health's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at -$2.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 92.86% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$12.7 million (down 105.87% YoY), while the FY2025 annual figure was $207.1 million, up 3160.49% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$2.3 million, up from -$19.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $276.3 million in Q4 2024, with the low at -$32.2 million in Q1 2025.
- The 5-year median for Cash from Financing Activities is $1.3 million (2023), against an average of $14.4 million.
- Peak annual rise in Cash from Financing Activities reached 1979.09% in 2024, while the deepest fall reached 2352.85% in 2024.
- Phibro Animal Health's Cash from Financing Activities stood at $3.7 million in 2022, then sank by 495.72% to -$14.7 million in 2023, then jumped by 1979.09% to $276.3 million in 2024, then tumbled by 106.87% to -$19.0 million in 2025, then jumped by 87.88% to -$2.3 million in 2026.
- Business Quant data shows PAHC's Cash from Financing Activities at -$2.3 million in Q1 2026, -$19.0 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 125.68 Mn | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.30 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Sep 30, 2025 | 16.34 Mn |
| Sep 30, 2025 | 16.34 Mn |
| Jun 30, 2025 | -7.77 Mn |
| Jun 30, 2025 | -7.77 Mn |
| Mar 31, 2025 | -32.22 Mn |
| Mar 31, 2025 | -32.22 Mn |
| Dec 31, 2024 | 276.32 Mn |
| Dec 31, 2024 | 276.32 Mn |
| Sep 30, 2024 | -29.20 Mn |
| Sep 30, 2024 | -29.20 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Dec 31, 2023 | -14.71 Mn |
| Dec 31, 2023 | -14.71 Mn |